⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Createrna Science and Technology and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Createrna Science and Technology
↗Wuhan, China
Createrna Science and Technology is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of small-molecule medicines. The company employs a dual-driven strategy focusing on both R&D pipeline development and the construction of proprietary drug discovery platforms, covering the entire process from proof-of-concept and candidate screening to preclinical and clinical development.
With R&D centers in Wuhan and Shanghai, Createrna maintains a robust pipeline of over 20 therapeutic candidates targeting high unmet medical needs. Their primary therapeutic areas include cardiovascular, respiratory, autoimmune, inflammatory, and kidney diseases. The company is backed by prominent investors and actively engages in international collaborations to advance its innovative drug portfolio.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$70M
Investors:Lilly Asia Ventures, Vivo Capital, Hechuang Era Private Equity Fund Management, Irobust Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:8
Trial Phases:Phase 1: 5 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Joinn, Beijing University, Wuxi AppTec
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Yaning Wang - CEO
LINKS
Website:createrna.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Createrna Science and Technology. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.